ReviewDiabetes & vascular disease research2019

Dipeptidyl peptidase-4 inhibitors and cardiovascular and renal disease in type 2 diabetes: What have we learned from the CARMELINA trial?

Nordin Mj Hanssen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.